Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating tumor cells (CTCs) in women with high risk, HER2 nonamplified, early breast cancer.
Introduction
Breast cancer is the most common type of cancer in women worldwide, with approximately half a million deaths each year [1] . Although the prognosis of early-stage breast cancer has clearly improved over the last decades, still 20%-30% of patients will develop disease recurrence and die of breast cancer despite primary surgery and adjuvant systemic treatment aiming to eradicate minimal residual disease [2] .
When we designed the Treat circulating tumor cell (CTC) trial, adjuvant trastuzumab for 1 year was the standard of care for women with HER2-amplified or overexpressing breast cancer [3] . At that time, data from retrospective analyses of the NSABP B31 and NCCTG N9831 trials [4, 5] suggested that women with breast cancer not confirmed as HER2-amplified or overexpressing after central pathology review had similar benefit from adjuvant trastuzumab compared with women with centrally confirmed HER2-amplified or overexpressing tumors. Thus, it was hypothesized that trastuzumab might benefit women with HER2 nonamplified tumors. Furthermore, it was suggested that trastuzumab might benefit women with HER2 nonamplified breast cancer by targeting HER2-low expressing stem cells [6] or HER2-overexpressing CTCs [7] . Based on the above data, the NSABP B47 trial was designed to evaluate whether trastuzumab can improve iDFS in women with HER2-low breast cancer when added to standard adjuvant chemotherapy [8] . HER2-low was defined as 1þ by immunohistochemistry (IHC) or 2þ by IHC but fluorescent in situ hybridization negative.
To create more data before launching a large phase III trial testing the same hypothesis we designed the European Organization for Research and Treatment of Cancer (EORTC) 90091-10093 BIG 1-12 Treat CTC trial, a randomized phase II trial investigating whether six cycles of trastuzumab treatment decreases the detection rate of CTC in patients with HER2-negative primary BC when compared with observation [9] .
Here we report the Treat CTC trial results following the Independent Data Monitoring Committee (IDMC) recommendation for the closing of the study due to futility for the primary end point.
Methods

Patients and design
This randomized phase II trial was conducted in 70 hospitals and 6 CTC laboratories in 5 European countries. Patients eligible for the trial were women aged !18 years with HER2-negative primary nonmetastatic breast cancer (defined by the 2007 American Society of Clinical Oncology/College of American Pathologists guidelines) [10] . Eligible patients were high risk patients that according to their treating physician needed to have (neo)adjuvant chemotherapy. The time between the end of adjuvant chemotherapy or definitive surgery after neoadjuvant chemotherapy and registration had to be between 3 and 24 weeks. Patients needed to have adequate baseline cardiac function [left ventricular ejection fraction (LVEF) !55%] assessed either by echocardiography or MUGA scan within 2 weeks before randomization.
Before registration, all patients gave signed informed consent for the clinical trial and had a peripheral blood sample taken for CTC detection and analysis of the HER2 protein expression of CTCs using Cellsearch V R technology [11] . In case no CTCs were found, the patient was considered ineligible for this trial. In case !1 CTC/15 ml blood was found and confirmed following central image review as previously reported [9] , the primary breast tumor material was sent to the central pathology laboratory for confirmation of the HER2-negative status of the primary breast tumor. HER2 protein expression on CTCs was scored as 0, 1þ, 2þ and 3þ and HER2 þ CTCs were defined as those that were 2þ/3þ following central image review, as previously reported [9] . Patients were eligible for this trial irrespective of CTCs HER2 status.
The trial was approved by national ethics committees and local ethics committees in all participating centers and registered in ClinicalTrials.gov, under number NCT01548677.
Treat CTC laboratories
CTCs detection was carried out in six national laboratories using the validated Cellsearch V R technology; 4 in Germany, 1 in France and 1 in Belgium. Details about the Treat CTC laboratories quality assurance are provided in supplementary Methods, available at Annals of Oncology online.
Randomization and treatment
In this open label study, the randomization procedure was centrally generated and transferred by the EORTC online randomization system based on the minimization method. Randomization was stratified by institution, locally confirmed estrogen receptor (ER) status and adjuvant versus neoadjuvant chemotherapy. Patients were randomized in a 1 : 1 ratio to six cycles of trastuzumab intravenously every 3 weeks (one cycle at loading dose of 8 mg/kg followed by five cycles at 6 mg/kg) versus 18 weeks of observation. During trastuzumab treatment, cardiac function was monitored every 9 weeks by either echocardiography or MUGA scan in accordance with the technique chosen at baseline. In case of cardiac function decrease, trastuzumab treatment was adapted according to the cardiac function flowchart (supplementary Figure S1 , available at Annals of Oncology online).
Outcomes
The study's primary end point was the CTC detection rate at week 18 based on central review confirmation. Secondary end points included invasive disease-free survival (iDFS) and overall survival (OS) and safety, with a focus on cardiac safety. iDFS was calculated as the time between randomization and the occurrence of an invasive disease recurrence [including any invasive ipsilateral breast tumor, local/regional invasive relapse, distant recurrence, invasive contralateral breast cancer, second primary invasive cancer (nonbreast)] or death (any cause). Patients who did not experience an event were censored at the time of their last followup. OS was calculated from randomization to the date of death (any cause). Patients alive at the time of analysis were censored at the last date they were known to be alive. Toxicity was captured using the international Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.
Statistics
With 156 planned assessable patients, the study was designed to detect with 82% power a decrease in CTC detection rate at week 18 from 30% in the observational arm to 15% in the trastuzumab arm (one-sided a of 10%). An interim analysis for futility and superiority was planned after half of the required number of assessable patients was randomized. However, the interim look was carried out sooner than planned following the recommendation of an IDMC, and led to the closing of the study accrual due to futility. Patients were given the option to continue their treatment, and were followed for assessment of the CTC test at week 18 as described in the protocol.
The effect of trastuzumab on the CTC detection rate at week 18 was summarized by the odds ratio and its corresponding one-sided 90% confidence interval, estimated using a logistic regression model. The primary comparison used a one-sided Fisher's exact test on the data from randomized patients with assessable test results at week 18. A sensitivity analysis was carried out including data from patients who went off treatment without an evaluable CTC blood test carried out at treatment discontinuation but who were considered as having an event at week 18.
The median time to event end points were estimated by the KaplanMeier method. No comparison between treatment arms was done for these end points due to the small number of patients with events.
All analyses were carried out using SAS software, version 9.4 (SAS Institute).
Results
Between 30 April 2013 and 17 October 2016, 1317 patients were enrolled at 70 sites in 5 European countries. A total of 1254 patients were deemed ineligible, mostly due to a negative CTC test at screening (n ¼ 1144, Figure 1 ; supplementary Table S1 , available at Annals of Oncology online). In total, 95 (7.2%) had detectable CTC(s) after completion of primary tumor surgery and (neo)adjuvant chemotherapy of whom 63 (4.8%) patients were randomly assigned to trastuzumab treatment (n ¼ 32) or observation (n ¼ 31). No statistically significant difference in CTC detection rate according to the time window between the end of (neo)adjuvant chemotherapy and the timing of blood draw was observed (supplementary Methods and Results, available at Annals of Oncology online). Baseline characteristics were balanced between the two treatment arms ( Table 1 ). The median patient age was 52 years (range 31-69). The majority of patients had lymph node positive disease (82.5%) and 68.3% of patients had ERþ tumors. The distribution of patients that received chemotherapy in the neoadjuvant and adjuvant setting was equal. The clinical cut-off date for this report was 3 April 2017.
Circulating tumor cells
The median number of detected CTCs in the blood of randomized patients after central review was 1, both overall and within the randomized groups (Interquartile range, IQR for the trastuzumab arm: 1-2 and for the observational arm: 1-3). Fifteen patients (23.8%) had at least one HER2 þ CTC; 6 (19.4%) in the trastuzumab arm and 9 (28.1%) in the observational arm. The median number of HER2þ CTCs was one both overall and within the two arms. Except for 1 patient with only 1 out of the 2 CTCs being HER2þ, for all other 14 patients all their CTCs were HER2þ.
Compliance
All patients complied with their allocated to treatment. In the trastuzumab arm, treatment was completed as planned for 27 out of 32 patients (87.1%), while 28 out of 31 (87.5%) patients completed the 18-week observation period. Eight patients did not complete the treatment or observation period as per protocol, five patients due to disease progression (n ¼ 3 in trastuzumab arm versus n ¼ 2 in observational arm), one patient due to death not attributable to disease progression or toxicity (trastuzumab arm), one patient due to personal decision (observational arm) and one patient due to start of a new anticancer treatment without confirmed disease progression (observational arm). The resulting median overall relative dose intensity of trastuzumab was 99.8%.
Safety
The safety profile was within the range of what is expected with trastuzumab. Three patients experienced a left ventricular ejection fraction (LVEF) drop below the pre-specified 55% boundary, yet without a !10 point difference when compared with baseline; thus no treatment delays or interruptions were observed in the trastuzumab arm due to cardiac toxicity. Adverse events !grade 3 occurred in six patients (19.4%) in the trastuzumab arm versus 2 (6.3%) in the observational arm (supplementary Table S2 , available at Annals of Oncology online). One patient in the trastuzumab arm died from bilateral pneumonia, attributed mostly to her history of radiation-induced lung disease. Adverse events did not result in discontinuation of treatment. Furthermore, there were no toxic deaths, and we did not observe any new safety signals for trastuzumab.
Efficacy CTC detection at week 18
Fifty-eight (92%) of the 63 randomized patients were assessable for the primary analysis of the CTC detection rate at week 18, 29 patients in each arm. For 5 patients the week 18 CTC test results were not available, due to progressive disease (PD) (n ¼ 2), death (n ¼ 1), start of a new anticancer treatment (n ¼ 1) and scheduling issues (n ¼ 1).
At week 18, CTCs could still be detected in 9 patients (Table 2;  supplementary Table S3 , available at Annals of Oncology online): 5 out of 29 patients (17.2%) randomized in the trastuzumab arm and 4 out of 29 (13.8%) in the observational arm (OR 1.30, 95% CI 0.31-5.40, one-sided Fisher's exact test P ¼ 0.765). Of these patients, there was only one with at least 1 HER2þ CTC. The sensitivity analysis showed a similar result (OR 1.04, 95% CI 0.32-3.42, one-sided P ¼ 0.644). When we focused on the 15 patients with at least one HER2þ CTC at study entry (6 patients in the trastuzumab and 9 patients in the observation arm), only 1 patient had detectable CTC at week 18 (observation arm).
Invasive disease-free and OS
With a median follow-up of 13 months (IQR 4-16.5), 13 months in the trastuzumab arm (IQR 4-16.5) versus 10 months in the observational arm (IQR 4-16), 4 out of 31 patients (12.9%) in the trastuzumab group and 4 out of 32 (12.5%) in the observation group had been diagnosed with an iDFS event (supplementary Table S4 , available at Annals of Oncology online). The 1-year iDFS was 93.8% (95% CI 77.3-98.4) in the observational arm versus 84.8% (95% CI 63.4-94.2) in the trastuzumab arm (Figure 2) .
At data cut-off, a total of 6 patients had died (4 in trastuzumab arm versus 2 in the observational arm, supplementary Figure S2 , available at Annals of Oncology online), 5 due to PD and 1 for reasons neither due to breast cancer nor due to treatment toxicity.
Clinical outcome in patients with positive CTCs at week 18
Of the nine patients with positive CTCs at week 18, two out of five patients in the trastuzumab arm developed distant metastases and subsequently died, while in the observational arm one patient developed an invasive locoregional recurrence and one patient was diagnosed with distant metastases and died (Table 2) .
Discussion
This study did not demonstrate that trastuzumab could significantly decrease the detection rate of CTCs in women with HER2 nonamplified breast cancer following (neo)adjuvant chemotherapy and surgery. After 18 weeks, CTCs could still be detected in 9 out of 58 patients with detectable CTCs; 5 of 29 in the trastuzumab arm and 4 of 29 in the observation arm. The 1-year iDFS was 94% in the observation arm versus 85% in the trastuzumab arm. The safety profile was as expected with no observed grade 2-4 cardiac events in the trastuzumab arm. Our trial was stopped following recommendation of the IDMC due to futility for the primary end point.
The recently reported NSABP-B47 also failed to demonstrate an improvement of iDFS in favor of trastuzumab in women with HER2-low breast cancer [8] . Indeed, after a median follow-up of 46 months, the 5 year iDFS was 89.2% for the chemotherapy arm versus 89.6% for the chemotherapy and trastuzumab arm (hazard ratio 0.98, 95% CI 0.77-1.26). Of note, in this trial a much larger number of patients were exposed to the 'experimental drug' trastuzumab compared with the Treat CTC. Thus, the NSABP B47 and the Treat CTC trial both failed to confirm the hypothesis that adjuvant trastuzumab can benefit women with HER2 nonamplified early breast cancer. These results are consistent with results from trials evaluating the role of anti-HER2 agents in metastatic breast cancer in which women with HER2 nonamplified metastatic breast cancer did not benefit from single agent trastuzumab [12] or from the addition of lapatinib to letrozole as first-line therapy [13] .
It has been suggested that trastuzumab might benefit women with HER2-negative primary tumors by eliminating HER2 overexpressing CTCs [7, 14] . However, in our study, only 15 out of the 63 randomized patients (24%) had at least one HER2/3þ CTC and due to the small number of patients with HER2þ CTC no claim can be made for the effect of trastuzumab on this subgroup of patients. The major limitation of our study was the low CTC detection rate (7.2%) that necessitated screening many patients to randomize only few. When we initiated the Treat CTC trial, CTC detection by CellSearch V R was the only blood-based biomarker with prospective clinical validation in a large number of patients, both for metastatic [15] and nonmetastatic [16] settings. Another limitation of our study was that the majority of patients included had only 1 CTCs per 15 ml of blood analyzed, which might raise concerns about the consistency of image interpretation among different laboratories. To address this issue, we carried out an inter-reader variability ring study before starting the Treat CTC trial [17] , and we implemented continuous laboratory personnel training and real-time central CTC image review. Only patients with CTCs confirmed by central image review were eligible to enter the study. The central image review procedure through a web-based platform created by the EORTC specifically for this study, as well as the continuous quality control of the Treat CTC laboratories [9] , ensures the high quality of our trial results. Moreover, it is known that one CTC may be detected in healthy women [11] , so the possibility of including women based on a false positive test result in this trial cannot be excluded. Finally, a third limitation of our study was the low number of CTCpositive patients at week 18. This might be partly due to the effective hormonotherapy in patients with ERþ/HER2À tumors that has eliminated the CTCs. Another reason might be the fact that patients in this setting have low number of CTCs and the CellSearch V R technology is not sensitive enough for their consistent detection in serial blood draws. Newer technologies such as circulating tumor DNA might be more sensitive in this setting [18] . CTC or ctDNA assays might allow earlier treatment that can prevent or delay disease relapse. This hypothesis needs to be prospectively confirmed. was supported by a donation from the Fondation Contre le Cancer from Belgium through the EORTC Cancer Research Fund. The trial was conducted in collaboration with the BIG.
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